Rising Incidence of Diabetes in Children Amidst COVID-19: A Comprehensive Analysis

By HEOR Staff Writer

July 28, 2023

The COVID-19 pandemic has had far-reaching implications, with recent reports indicating a surge in the incidence of pediatric diabetes. To gain a clearer understanding of this association, a systematic review and meta-analysis of various studies published in English was conducted. 

The analysis included 42 studies, covering 102,984 incident diabetes cases. The results revealed a significant increase in the incidence rate of type 1 diabetes and diabetic ketoacidosis (DKA) in children and adolescents during the first two years of the pandemic compared to the pre-pandemic period. 

While the exact mechanism linking COVID-19 to the onset of diabetes remains unclear, potential factors might include lifestyle changes, stress, social isolation, and disruptions in healthcare access due to pandemic containment measures. 

These findings underscore the urgent need for increased resources and support for the growing number of children and adolescents with diabetes.  Future studies are required to determine whether this trend continues, and to shed light on the possible underlying mechanisms explaining these temporal changes. 

 

The increased incidence of DKA at diagnosis highlights the need to identify gaps in the pathway from the onset of diabetes symptoms to diagnosis. This information is crucial for developing effective strategies to prevent DKA at diagnosis in children. 

 

 

Reference url

Recent Posts

Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthrough Treatment

By HEOR Staff Writer

February 4, 2026

Datroway metastatic breast cancer treatment has gained Priority Review from the US Food and Drug Administration (FDA) for first-line use in adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) ineligible for PD-1/PD-L1 inhibitors. This milestone for AstraZeneca and ...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk

By HEOR Staff Writer

February 2, 2026

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysis of clinical and real-world data, that glucagon-l...
Expansion of Generic Medicines Authorization in Portugal
928 New Medicines Authorizations Boost Portugal's Health Access In 2025, Portugal's National Authority for Medicines and Health Products (